We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunotherapy Slows Tumor Growth in Prostate Cancer Model

By LabMedica International staff writers
Posted on 01 Sep 2017
Print article
Image: A molecular ribbon structure of prostate-specific membrane antigen (PSMA) (Photo courtesy of Wikimedia Commons).
Image: A molecular ribbon structure of prostate-specific membrane antigen (PSMA) (Photo courtesy of Wikimedia Commons).
Cancer researchers have developed a novel immunotherapy technique based on synthetic DNA plasmids that successfully controlled tumor growth and prolonged survival in a mouse prostate cancer model.

The protein prostate-specific membrane antigen (PSMA) is expressed at high levels on malignant prostate cells and is likely an important therapeutic target for the treatment of prostate cancer. Current immunotherapy approaches to target PSMA include peptide, cell, vector, or DNA-based vaccines as well as passive administration of PSMA-specific monoclonal antibodies (mAb). Conventional mAb immunotherapy has numerous logistical and practical limitations, including high production costs and a requirement for frequent dosing due to short mAb serum half-life.

In order to overcome the problem of short mAb half-life in circulation, investigators at The Wistar Institute (Philadelphia, PA, USA) devised a novel strategy of antibody-based immunotherapy that utilized synthetic DNA plasmids to encode a therapeutic human mAb that targeted PSMA. The DNA in the plasmids enabled the host animal to produce the therapeutic mAb in a sustained manner.

The investigators reported in the August 17, 2017, online edition of the journal Cancer Immunology, Immunotherapy that electroporation-enhanced intramuscular injection of the DNA-encoded mAb (DMAb) plasmids into mice led to the production of functional and durable levels of the anti-PSMA antibody. The anti-PSMA produced in vivo controlled tumor growth and prolonged survival in the mouse model. The healing effect was likely mediated by antibody-dependent cellular cytotoxicity (ADCC) with the aid of NK (natural killer) cells.

"This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer," said senior author Dr. David B. Weiner, director of the Vaccine & Immunotherapy Center at The Wistar Institute. "There is a great need for such new approaches for prostate disease as well as many other cancers. As recent data suggest, PSMA is an important cancer antigen expressed on many human prostate, bladder, renal as well as ovarian cancers, so additional study of the possible benefits of this therapy are important."

Related Links:
The Wistar Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.